Biotechnology
News Category
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform
VERAXA Biotech announced the appointment of Dr. Christoph Erkel as Chief Scientific Officer, bringing extensive experience in antibody therapeutics to...
VERAXA Biotech Receives Positive Regulatory Feedback from Germany for BiTAC®-TCE Development
VERAXA Biotech's lead BiTAC®-TCE program gains regulatory clarity from Germany's Paul-Ehrlich-Institute, reducing development uncertainty as the compa...
Onco-Innovations Advances Precision Oncology with ONC010 for Biomarker-Selected Cancers
Onco-Innovations is developing ONC010, a nanoparticle-encapsulated PNKP inhibitor for biomarker-selected cancers, aligning with the industry shift tow...
Lantern Pharma Receives U.S. Patent Allowance for LP-184 Biomarker-Based Cancer Treatment Methods
Lantern Pharma obtained a U.S. patent allowance for methods using a three-gene biomarker signature to select patients for its investigational therapy ...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform
VERAXA Biotech AG appointed Christoph Erkel as Chief Scientific Officer to lead the development of its BiTAC platform for solid tumor cancer therapies...
iOrganBio Appoints Lee L. Rubin, Ph.D. to Scientific Advisory Board to Advance Neurological Cell Manufacturing
The appointment of Harvard stem cell expert Lee L. Rubin, Ph.D., to iOrganBio's Scientific Advisory Board is expected to accelerate the company's AI-p...
BioAdaptives Completes Manufacturing Readiness for Wellness Product Launch
BioAdaptives has finalized commercial manufacturing and logistics for its MyndSystem and Xcellara wellness platforms, targeting the global cognitive a...
Creative Biolabs Expands Microfluidics Portfolio to Accelerate High-Throughput Antibody Discovery
Creative Biolabs expands its integrated microfluidics platform to improve high-throughput antibody screening, single-cell analysis, and immune checkpo...
Quantum BioPharma Advances Two-Pronged Strategy Against Brain Disorders with Novel MS Drug and Alcohol Intoxication Supplement
Quantum BioPharma is developing Lucid-MS, a novel therapy for multiple sclerosis, and unbuzzd, a dietary supplement to reduce alcohol intoxication eff...
Oncotelic Therapeutics Publishes Preclinical Data Supporting Intravenous Cancer Therapy Sapu003
Oncotelic Therapeutics announced the publication of preclinical data for its intravenous everolimus formulation Sapu003, which could overcome limitati...
Kairos Pharma and Bayer Collaborate to Test Combination Therapy for Advanced Prostate Cancer
Kairos Pharma has partnered with Bayer to evaluate its antibody ENV-105 in combination with XOFIGO for metastatic castration-resistant prostate cancer...
VERAXA Biotech Advances BiTAC-TCE Development with Positive Regulatory Feedback from Germany
VERAXA Biotech received Scientific Advice from Germany's Paul-Ehrlich-Institute supporting its BiTAC-TCE program, reducing development uncertainty bef...
VivoSim Labs Raises $4 Million in Private Placement with Healthcare-Focused Institutional Investor
The announcement is important as it provides VivoSim Labs with capital for working capital and general corporate purposes, potentially accelerating it...
Greenwich LifeSciences Advances Phase 3 Trial for Breast Cancer Immunotherapy GLSI-100
Greenwich LifeSciences reported positive progress in its Phase 3 FLAMINGO-01 trial for GLSI-100, with DSMB recommendation to continue, expanded enroll...
Quantum BioPharma Develops Two-Pronged Attack on Brain Disorders Affecting Millions
Quantum BioPharma is advancing therapies for multiple sclerosis and alcohol intoxication, targeting significant unmet needs in neurological disorders.
American Fusion Secures Texas Certificate of Registration for Texatron Fusion Engine Testing
American Fusion Inc. received a Texas DSHS Certificate of Registration for industrial radiation machines, enabling testing of its Texatron Fusion Engi...
Study Finds No Evidence That Mobile Phones Can Cause Brain Cancer
A WHO-commissioned review of 13 studies found no link between mobile phone use and brain cancer, shifting focus to treatment development for the disea...
Quantum BioPharma Reaches Halfway Point in MS Imaging Study with Encouraging Early Data
Quantum BioPharma reports that a key imaging study for its MS drug candidate Lucid-MS has reached 50% patient enrollment, with preliminary data showin...
GeoVax Highlights Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy
GeoVax Labs announces that its GEO-MVA vaccine platform aligns with the HHS/ASPR's five-year strategy for medical countermeasure preparedness, emphasi...
VERAXA Biotech Receives Regulatory Feedback on BiTAC-TCE Cancer Therapy Platform from German Authority
VERAXA Biotech announced it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute for its BiTAC-TCE cancer therapy platform, providing ...
VERAXA Biotech Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
VERAXA Biotech AG received Scientific Advice from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, providing clarity for non-clinical deve...
Regentis Biomaterials Receives Japan Patent Allowance for GelrinC Manufacturing Technology
Regentis Biomaterials announced a patent allowance in Japan for its proprietary manufacturing process for GelrinC, a regenerative treatment for cartil...
MindBio Therapeutics Advances Voice-Based AI Tech for Real-Time Impairment Detection
MindBio Therapeutics is developing an AI-powered voice analysis platform for rapid, non-invasive drug and alcohol impairment detection, targeting a gr...
Study Links Gut Microbial Metabolites to Enhanced Cancer Immunotherapy Sensitivity
A recent study has identified that metabolites produced by gut bacteria can improve responses to cancer immunotherapy, offering potential for personal...
SS Innovations Appoints Veteran Medtech Finance Executive as CFO Amid Global Robotic Surgery Expansion
SS Innovations International has appointed Sarah M. Romano as CFO, bringing public-company finance experience as it advances FDA clearance for its SSi...
Creative Biolabs Combines Microfluidics and Electrochemical Biosensors to Advance POCT Diagnostics
Creative Biolabs has announced an integrated development platform that merges microfluidics with electrochemical biosensors to enhance point-of-care t...
BioAdaptives Details Xcellara Platform Strategy Ahead of XcellaraHeart Launch
BioAdaptives outlines the scientific strategy behind its Xcellara cellular wellness platform, which combines a stem cell mobilization base with tissue...
NeuroOne Expands Drug Delivery Program Through Mayo Collaboration for Pediatric Brain Cancer Trial
NeuroOne Medical Technologies announced a collaboration with Mayo Clinic to support a clinical trial for pediatric diffuse midline glioma, using its d...
Oncotelic Therapeutics Launches AI-Powered GMP Manufacturing Platform to Aid Biotech Drug Development
Oncotelic Therapeutics announced an AI-powered manufacturing services platform combining its PDAOAI architecture with robotics from TechForce Robotics...
Quantum BioPharma Advances Multiple Sclerosis Therapy LUCID-MS with Phase 2 Trial Plans
Quantum BioPharma's LUCID-MS shows promise as a potential first-in-class neuroprotective therapy for multiple sclerosis, advancing to Phase 2 trials a...
VERAXA Biotech’s AI Collaboration Could Enhance Its Oncology Platform and Reduce Drug Development Risks
VERAXA Biotech’s partnership with Ardigen to apply AI to its BiTAC(R) platform may improve target discovery and validation, potentially giving the com...
Tonix Pharmaceuticals Publishes Mpox Research Supporting TNX-801 Vaccine Development
New preclinical research published in the Journal of Virology shows mpox clade IIb is up to 100,000 times less virulent than clade IIa, supporting Ton...
Nuvectis Pharma Prices $100 Million Public Offering to Advance Pipeline
Nuvectis Pharma announced the pricing of a $100 million public offering to fund development of its NXP100, NXP200, and NXP900 programs, highlighting i...
Kairos Pharma Reports Favorable Interim Phase 1 Safety Data for ENV-105 in EGFR-Mutated Lung Cancer
Kairos Pharma announced promising interim safety results from its Phase 1 trial of ENV-105 combined with osimertinib for advanced EGFR-mutated non-sma...
NeuroThera Labs Initiates Phase IIb Clinical Trial at Hannover Medical School for Tourette Syndrome Treatment
NeuroThera Labs has started a Phase IIb trial for SCI-110, a cannabinoid-based treatment for Tourette Syndrome, at Hannover Medical School, aiming to ...
Earth Science Tech Inc. Leverages Telehealth and Peptide Therapies to Strengthen Market Position
Earth Science Tech Inc. is capitalizing on the growing telehealth and peptide therapy markets, projected to reach $251.5 billion and $249 billion resp...
Formycon and OneSource Specialty Pharma Form Strategic Manufacturing Partnership for Biosimilars
Formycon AG and OneSource Specialty Pharma have announced a strategic manufacturing partnership to produce biosimilars, leveraging OneSource's integra...
Quantum BioPharma Advances LUCID-MS Therapy for Multiple Sclerosis into Phase 2 Trials
Quantum BioPharma's LUCID-MS, a novel therapy targeting myelin restoration in multiple sclerosis, has shown favorable safety in Phase 1 studies and is...
Quantum BioPharma Advances LUCID-MS Toward Phase 2 Trial for Multiple Sclerosis
Quantum BioPharma is progressing its neuroprotective therapy LUCID-MS, which targets myelin loss in multiple sclerosis, into Phase 2 clinical trials a...
Silo Pharma Subsidiary QwikAgents Joins AMD AI Developer Program
Silo Pharma's subsidiary QwikAgents has been accepted into AMD's AI Developer Program, gaining access to cloud credits and tools to accelerate its AI ...
VERAXA Biotech’s AI Partnership Could Accelerate Cancer Therapy Development
VERAXA Biotech has partnered with AI-focused Ardigen to use artificial intelligence for target discovery in its BiTAC cancer therapy platform, potenti...
DN Group AG Subsidiary Algene Achieves Milestone with First Microalgae Harvest, Enters Series Production
Algene Holding SE, a subsidiary of DN Group AG, has successfully completed its first harvest of high-purity microalgae, yielding 4,500 liters, and is ...
VERAXA Biotech Partners With Ardigen to Advance AI-Driven Cancer Drug Development
VERAXA Biotech (NASDAQ: VRXA) has partnered with Ardigen to integrate AI into its BiTAC pipeline, aiming to enhance target selection and reduce toxici...
NanoViricides Receives Ethics Approval for Phase II Ebola Trial in DRC
NanoViricides has received National Ethics Committee approval in the Democratic Republic of the Congo for a Phase II clinical trial of its oral NV-387...
Tonix Pharmaceuticals Expands TONMYA Medicare Coverage to 145 Million Lives
Tonix Pharmaceuticals announced a major managed Medicare agreement for TONMYA, expanding pharmacy coverage to approximately 145 million covered lives,...
VERAXA Biotech Partners with Ardigen to Leverage AI for Enhanced Cancer Drug Development
VERAXA Biotech AG has partnered with Ardigen S.A. to integrate artificial intelligence into its BiTAC pipeline, aiming to improve target selection and...
Onco-Innovations Completes Analytical Reference Standard Program for ONC010, Advancing CMC Framework
Onco-Innovations Limited announced the completion of its analytical reference standard preparation program for ONC010, a key step in strengthening its...
VERAXA Biotech Appoints Carl von Halem as Interim CFO Amid Leadership Transition
VERAXA Biotech announced the appointment of Carl von Halem as interim CFO, leveraging his experience in corporate finance and life sciences to guide t...